This study investigates pancreatic cancer with liver metastasis. It focuses on evaluating a multimodal ablation system.
The study evaluates the safety and effectiveness of combining multimodal ablation therapy with immunotherapy and chemotherapy.
- Who can participate: Adults aged 18 to 70 years with pancreatic cancer that has spread to the liver are eligible. Participants must have up to three liver tumors, each no larger than 3 cm. They must also have a good overall health status.
- Study details: Participants will undergo treatments that include multimodal ablation therapy combined with immunotherapy and chemotherapy.